Welcome to our dedicated page for Integer Hldgs news (Ticker: ITGR), a resource for investors and traders seeking the latest updates and insights on Integer Hldgs stock.
Integer Holdings Corporation (NYSE: ITGR) is a premier global player in the medical device outsourcing (MDO) industry. With a reputation for excellence in innovation and manufacturing, Integer delivers comprehensive end-to-end solutions that both enhance patient lives and meet the needs of their customers. The company's core business revolves around the creation of medical device components, which are developed and manufactured for original equipment manufacturers (OEMs) across various medical sectors including cardiac, neuromodulation, vascular, portable medical, and orthopedics markets.
In addition to their medical device segment, Integer also operates through Electrochem, an entity focused on developing custom batteries for niche applications in energy, military, and environmental markets. Their portfolio includes renowned brands such as Greatbatch™ Medical and Lake Region Medical™. The company has a substantial footprint in the United States, earning over half of its revenue domestically.
Integer has recently marked significant milestones, including its acquisition of InNeuroCo, Inc., which has bolstered its neurovascular catheter capabilities. The third quarter of 2023 saw Integer reporting organic sales growth of 18% and a 39% increase in adjusted operating income. The company has ongoing strategic expansions, particularly in Europe, with new facilities in Ireland designed to enhance their high-volume manufacturing capacity and R&D capabilities.
Financially, Integer continues to show robust growth with an increase in full-year sales outlook. Their recent acquisition of Pulse Technologies underscores their strategy to enhance precision micro-machining capabilities for medical device components, further expanding their market reach and development capacity. Integer also anticipates strong financial performance in 2024, with projected sales growth between 9% and 11%, and adjusted operating income growth ranging from 13% to 20%.
The company actively engages with investors, providing real-time updates through their comprehensive Investor Relations section on their website. They have streamlined their operations and expanded their capabilities to ensure a seamless transition from R&D to operations for their global clientele.
Learn more about Integer at www.integer.net.
Integer Holdings (NYSE:ITGR) reported strong Q4 and full-year 2024 results, with Q4 sales increasing 11% to $449 million and full-year sales up 10% to $1.717 billion. The company's Q4 GAAP income from continuing operations rose 23% to $33 million, while adjusted EBITDA grew 11% to $95 million.
For the full year 2024, GAAP income from continuing operations increased 36% to $121 million, and adjusted EBITDA rose 19% to $361 million. The company generated $205 million in operating cash flow. Integer completed the acquisition of Precision Coating for $152 million and signed an agreement to acquire VSi Parylene for $28 million.
Looking ahead to 2025, Integer expects 8-10% sales growth with expanding margins. The Cardio & Vascular segment showed strong performance with 15% growth in Q4 2024, while Cardiac Rhythm Management & Neuromodulation sales increased 11%.
Integer Holdings (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), has announced its participation in two upcoming investor conferences in March 2025.
President and CEO Joseph Dziedzic will present at the Raymond James & Associates' 46th Annual Institutional Investor Conference on March 5, 2025, at 11:00 a.m. ET in Orlando, Florida. Additionally, he will participate in a virtual fireside chat at the KeyBanc Capital Markets Healthcare Forum on March 19, 2025, at 9:45 a.m. ET.
Both presentations will be available via live webcast in the 'News & Events' section of Integer's Investor Relations website at investor.integer.net.
Integer Holdings has acquired Precision Coating from Katahdin Industries, , with the transaction closing on January 7, 2025. Precision Coating is a specialized provider of surface functionality enhancement services for patient-critical products in the Medtech industry.
Since 2006, the company has expanded through five strategic acquisitions: CHN Metal Finishing (2008), Medi-Solve (2008), Boyd Coatings Research (2015), N2 Biomedical (2021), and Providence Texture (2023). The company operates from four North American locations and one in Costa Rica.
Precision Coating's key offerings include GlideLine™ fluoropolymer coatings for medical devices, MICRALOX® patented anodic coatings for reusable medical instruments, and IonGuard® ion treatment for implants. The company has achieved nearly ten-fold growth through investments in data systems, automation, materials development, and international expansion.
Integer Holdings (NYSE: ITGR) will exhibit at MD&M West 2025 from February 4-6 at the Anaheim Convention Center, showcasing their medical device manufacturing capabilities at booth #1439. The company will demonstrate their expertise in cardio and vascular solutions, cardiac rhythm management, and neuromodulation products, including their global rapid prototyping services with two-week turnarounds.
A significant highlight is Integer's recent acquisition of Precision Coating for $152 million on January 7, 2025. This strategic move enhances Integer's capabilities with specialized surface coating technologies, including fluoropolymer, anodic coatings, ion treatment solutions, and laser processing. The acquisition aligns with Integer's tuck-in strategy and expands their service offerings to better serve customer needs.
The company will provide more details about the Precision Coating acquisition during their Q4 and full-year 2024 earnings call scheduled for February 20, 2025.
Integer Holdings (NYSE: ITGR), a leading medical device contract development and manufacturing organization, will showcase its innovations at the North American Neuromodulation Society (NANS) Annual Meeting from January 30 to February 1, 2025, in Orlando, Florida. At booth #213, Integer will present its latest advancements in neuromodulation and miniaturized active implantable medical devices (AIMDs).
The company will highlight its Xcellion® Gen 3 Fast Charge (FC) Lithium Ion implantable battery technology, which offers industry-leading battery runtime and can fully recharge in as little as 30 minutes. Integer aims to demonstrate its capabilities as a strategic partner for OEMs, focusing on accelerating and de-risking the path to market for novel implantable medical devices through their expertise in critical implantable technologies.
Integer Holdings (NYSE:ITGR) has announced its schedule for the release of fourth quarter and full year 2024 financial and operational results. The company will disclose the results on Thursday, February 20, 2025, at 7 a.m. Central Time (8 a.m. Eastern Time). Following the release, Integer's management team will host a webcast at 8 a.m. Central Time (9 a.m. Eastern Time) to discuss the results.
Integer Holdings (NYSE: ITGR) has announced that holders of its 2.125% Convertible Senior Notes due 2028 can convert their notes from January 1, 2025, through March 31, 2025. The conversion opportunity arose because the company's stock price exceeded 130% of the conversion price for at least 20 trading days within a 30-day trading period ending December 31, 2024.
The notes are convertible at a rate of 11.4681 shares of common stock per $1,000 principal amount, equivalent to a conversion price of approximately $87.20 per share. Upon conversion, holders will receive cash up to the principal amount, and either cash, shares, or a combination thereof for any remaining conversion value, at Integer's discretion.
Integer Holdings (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The event will take place from December 3-5, 2024, in New York City. President and CEO Joseph Dziedzic will deliver a presentation on Tuesday, December 3, 2024, at 10:30 a.m. EST. The presentation will be available through a live webcast, accessible via the Investor Relations section of Integer's website under 'News & Events' at investor.integer.net.
Integer Holdings (NYSE: ITGR) has completed the sale of its Electrochem business to Ultralife for $50 million in cash. The company will use the proceeds to reduce its outstanding debt. This divestiture transforms Integer into a pure-play medical technology company, focusing exclusively on its medical device contract development and manufacturing operations (CDMO). The strategic move aims to enable Integer to deploy additional capital in high-growth medtech markets.
Integer Holdings (NYSE: ITGR) announced key leadership changes effective Q1 2025. Payman Khales, current President of Cardio & Vascular, will become Chief Operating Officer, overseeing both product categories along with Global Operations and Manufacturing Strategy. Andrew Senn will succeed Khales as President of Cardio & Vascular. Under Khales' leadership since 2018, the Cardio & Vascular business achieved above-market growth. Senn brings 18 years of experience at Integer and extensive industry knowledge from various leadership roles.
FAQ
What is the current stock price of Integer Hldgs (ITGR)?
What is the market cap of Integer Hldgs (ITGR)?
What does Integer Holdings Corporation do?
What markets does Integer serve?
What are some of Integer's notable brands?
Where is Integer Holdings Corporation's primary market?
Has Integer Holdings Corporation made any recent acquisitions?
What recent financial achievements has Integer reported?
What are Integer's growth expectations for 2024?
What recent expansions has Integer undertaken?
How can investors access Integer's financial news?
What is Integer's mission?
